Therapeutic effects of topical 0.03% Tacrolimus ointment in children with refractory vernal keratoconjunctivitis in Middle East

ObjectiveThe purpose of this paper is to review the efficacy and safety profile in children treated with topical 0.03% Tacrolimus ointment for vernal keratoconjunctivitis in Middle East and to propose a treatment posology. According to recent studies, a complex non-IgE dependent mechanism plays a relevant role in the pathogenesis of vernal keratoconjunctivitis. Numerous cells and mediators have been found in the serum, conjunctiva and tears of patients with Vernal keratoconjunctivitis.DesignThis case series included 10 patients from a single centre, pediatric department of a tertiary hospital with active symptomatic vernal keratoconjunctivitis. All the patients had proliferative lesions and corneal involvement despite conventional medications, including topical steroids. All other medications, systemic and topical: steroids, antihistamines and cyclosporine, were unsuccessful. Patients were treated with topical 0.03% Tacrolimus ointment twice daily for 8 weeks and then once a day for the next two month followed by thrice a week for two months. The changes in symptoms and signs after treatment were evaluated, also the development of possible complications was assessed.ResultsThe results showed a significant reduction in signs and symptoms after 4 weeks of the treatment. Clinical resolution of giant papillae and corneal lesions were seen within eight weeks and no additional drug was required during that period, except tear substitutes. Treatment was continued for period of two months and then slowly reduced.ConclusionThe use of 0.03% Tacrolimus ointment is safe and effective in children refractory to conventional treatment of vernal keratoconjunctivitis even in high temperature climate as Middle East. Due to the effectiveness of the treatment, the dosage used may be proposed for conventional use.     

罂硝软膏的制备及质量控制

目的 :制备罂硝软膏 ,并建立质量控制方法。方法 :以硝酸甘油、盐酸罂粟碱、双氯芬酸钾为主药研制软膏剂 ,用紫外分光光度法及酸碱滴定法分别测定硝酸甘油、盐酸罂粟碱、双氯芬酸钾3组分的含量。结果 :硝酸甘油、盐酸罂粟碱、双氯芬酸钾的平均回收率分别为100 65 %、99 86 %、100 55 %,相对标准差分别为0 4945 %、0 1719 %、0 3205 %(n=3)。结论 :该软膏制备工艺可行 ,质量可控 ,性质稳定。     

联苯苄唑凝胶治疗婴儿花斑癣22例临床效果分析

目的总结分析1%联苯苄唑凝胶治疗婴儿花斑癣的临床疗效及不良反应。方法对22例婴儿花斑癣患者采用外用1%联苯苄唑凝胶治疗2周,总结分析其临床资料。结果外用1%联苯苄唑凝胶2周后,总有效率达到90.91%,真菌清除率达到86.36%。结论联苯苄唑凝胶治疗婴儿花斑癣安全、有效,不良反应少。     

雷帕霉素对人肝癌裸鼠原位移植瘤生长的抑制作用

目的探讨雷帕霉素对人肝癌裸鼠原位移植瘤生长的影响及其机制。方法建立人肝癌棵鼠肝原位移植瘤模型32只,随机分为空白对照组、FK506组、雷帕霉素常规剂量组和高剂量组。用药两周后观察肿瘤体积的变化,免疫组织化学法检测肝癌组织中增殖细胞核抗原(PCNA)、血管内皮细胞生长因子(VEGF)的表达。结果对照组、FK506组、雷帕霉素常规剂量组、高剂量组平均肿瘤体积分别为:(310．15±40．16)、(605．59±116．23)、(99．19±15．27)、(151．61±27．81) mm3。与对照组相比,雷帕常规剂量组及高剂量组肿瘤体积明显缩小,PCNA、VEGF的表达均显著下调(P<0．01);FKS06组肿瘤体积与对照组相比明显增大,差异有统计学意义(P<0．01),PC- NA、VEGF的表达与对照组相比差异无统计学意义(P>0．01)。结论雷帕霉素具有显著抑制肝癌生长的作用,其机制可能是抑制了肝癌细胞的恶性增殖及VEGF的产生。     

低剂量他克莫司治疗大鼠急性脊髓损伤的实验研究

目的：探讨低剂量他克莫司（tacrolimus，又名FK506）对大鼠急性脊髓损伤是否具有神经保护作用。方法：雄性Wistar大鼠72只，随机分为假手术组（12只）、损伤组（30只）和FK506治疗组（30只）。采用Allen’s打击法致伤大鼠T10脊髓，假手术组仅做椎板切除术。FK506治疗组在脊髓损伤后5min一次性经尾静脉注射FK5060．3mg／kg，其余两组以相同方法给予等量生理盐水。致伤后30min、6h、24h、48h、72h取伤段脊髓组织行病理观察及原位末端标记法（TUNEL）检测神经细胞凋亡，伤后1、3、7、14、21d行脊髓功能BBB评分和斜板实验。结果：伤后3、7、14、21d，FK506治疗组斜板实验和BBB评分明显优于损伤组，两组间比较差异有显著性（P〈0．05）；伤后各时间点FK506治疗组脊髓损伤区出血坏死较损伤组轻；伤后6、24、48、72h神经细胞凋亡FK506治疗组较损伤组明显减少，两组间比较差异有显著性（P〈0．05）。结论：在大鼠急性脊髓损伤后早期应用低剂量他克莫司（0．3mg/kg）治疗对神经具有保护作用，可减少神经细胞凋亡，减轻脊髓继发性损伤，促进脊髓功能恢复。     

冰蜜生肌膏对兔成纤维细胞增殖影响的实验研究

目的:观察冰蜜生肌膏促进体外培养兔成纤维细胞增殖的影响。方法:采用消化分离法进行兔成纤维细胞的原代培养,通过形态学和免疫组织化学的方法鉴定成纤维细胞。第3代纯化的成纤维细胞分为5组,空白对照组每孔加入等量的PBS,实验组每孔分别加入125、62·5、31·25、15·625mg/ml的冰蜜生肌膏提取液进行培养,培养24、48、72h后分别行MTT法检测每孔的光吸收值(OD值)。结果:冰蜜生肌膏提取液加入到成纤维细胞中培养24、48、72h后,经MTT法检测,不同浓度(浓度分别为125、62·5、31·25、15·625mg/ml)冰蜜生肌膏与对照组OD值比较差异有显著性统计学意义(P<0·05)。结论:15·625mg/ml浓度冰蜜生肌膏对成纤维细胞的生长有明显促进作用(P<0·05),药物浓度在15·625~62·5mg/ml时其作用随药物浓度升高而增加,并在浓度为62·5mg/ml时达到最大效应值(P<0·01),当药物浓度大于62·5mg/ml时则作用趋向于饱和,提示一定浓度范围内的冰蜜生肌膏药液能明显增加成纤维细胞数量,且促进作用和浓度呈显著依赖性。     

不同方法治疗压褥的临床效果比较

目的探讨不同方法治疗压疮的临床效果。方法将65例患者计Ⅱ～Ⅲ度溃疡84处按基本条件相当原则随机分成A、B、C三组，A组21例28处，伤口采用清创冲洗后，给予康惠尔水胶体敷料；B组23例30处，伤口采用湿润烧伤膏；C组21例26处，清创冲洗后，给予自制凡士林油纱敷料外敷溃疡面处。结果B组愈合率最高，且平均显效时间和愈合时间均较A、C两组明显缩短，且A、B组明显高于C组。结论采用清创冲洗后用湿润烧伤膏是治疗压疮较好的方法之一。     

外用他克莫司和吡美莫司的安全性

他克莫司和吡美莫司是新型钙调磷酸酶抑制剂药物,其外用制剂可用于治疗特应性皮炎。近年来,对这两种药物的安全性存有争议。现有的资料表明,外用他克莫司和吡美莫司安全性高,不引起皮肤萎缩,经皮吸收极少,无明显的系统免疫抑制作用,不会引起皮肤或系统的感染和肿瘤的发病率升高。     

利浦松软膏防治烧伤创面瘢痕120例疗效观察

目的 :观察利浦松软膏防治烧伤创面瘢痕的疗效。方法 :将利浦松软膏涂擦于烧伤愈合创面 ,观察瘢痕生长情况。结果 :12 0例烧伤病人创面显效 32例 ,有效 72例 ,无效 16例。结论 :利浦松软膏用于防治烧伤创面瘢痕疗效显著 ,方法简单 ,便于推广应用     

FK506 (tacrolimus) improves lung injury through inhibition of Fas-mediated inflammation

Objective To investigate whether FK506 (tacrolimus) can inhibit Fas- or A23187-induced interleukin (IL)-8 expression and cell death in A549 human alveolar epithelial cells, plus Fas-mediated acute lung injury in vivo. Methods Assays for IL-8, cell death, and caspase-3 activity were performed. A549 cells were treated with 25 μmol A23187 or 0.2 μg/ml agonistic anti-Fas antibody plus 5 ng/ml interferon-gamma (IFN-γ). Tacrolimus was treated at 0.1–10 ng/ml. For in vivo experiment, agonistic anti-Fas antibody (Jo2) at 2.5 μg/g was intratracheally instilled into C57BL/6 mice. Neutrophils and protein contents in bronchoalveolar lavage (BAL) fluid were measured within 24 h of instillation. Mice were orally treated with 32 mg/kg of tacrolimus 24 h and 1 h prior to instillation. Results Both Fas and A23187 caused significant IL-8 expression and cell death in A549 cells. Tacrolimus inhibited A23187-induced IL-8 expression alone while it protected all Fas-mediated responses. Mice instilled intratracheally with Jo2 at 2.5 μg/g had significant increases in neutrophils, protein contents in BAL fluid and in expression of chemoattractants for neutrophils. These increases were reversed by tacrolimus. Conclusions Tacrolimus serves as a therapeutic option for improving lung injury through inhibition of Fas-mediated inflammation. Received 7 November 2005; returned for revision 28 December 2005; accepted by G. Wallace 2 February 2006